Gibco™ CF6-Neo Mouse Embryonic Fibroblasts, irradiated 

Description

Manufactured by MTI-GlobalStem and equivalent to MTI-GlobalStem Cat. No. GSC-6005G, these MEF cells are isolated from CF1 x C57BL/6 hybrid mice, mitotically arrested by irradiation and tested to help ensure performance and minimize the risk of contamination. For neomycin-resistant MEFs that are inactivated by mitomycin C treatment, see CF6-Neo Mouse Embryonic Fibroblasts, MitC-treated. You may also choose from our broad selection of other MEFs to suit your application.

• Help save precious time with pre-inactivated, ready-to-use MEFs
• Culture ESCs and iPSCs with confidence using meticulously tested feeder cells
• Perform research involving drug selection using neomycin-resistant cells

Help save time with ready-to-use MEFs
Irradiated CF6-Neo MEFs help save time and trouble dealing with an animal facility, performing tedious, time-consuming dissections, and expanding and testing cells day after day, week after week. Focus on your research with these pre-inactivated, ready-to-use feeders.

Culture with meticulously tested feeder cells
Each lot of CF6-Neo MEFs is tested for bacteria, fungi, mycoplasma, and various mouse pathogens to minimize the risk of contamination. Each lot is also tested for post-thaw viability (typically greater than 95%) and ability to support mouse and human ES cells to help ensure robust and consistent performance in your research. These MEFs have successfully been used with ESC/iPSC lines from other species but should be tested for compatibility if used for such an application.

Perform research involving drug selection using neomycin-resistant cells
CF6-Neo MEFs express neoR from a pPGKneobPa transgene, making them highly resistant to neomycin and geneticin (G418). Each lot is tested for tolerance to various G418 concentrations, and the threshold range for survival is reported in the CoA to aid in designing experiments. Use these feeder cells to support undifferentiated ESC or iPSC culture while performing G418 selection.